Rega marang bathi mangsa ngarep Regulus (RGLS)
The expected price-to-earnings multiple of Regulus Therapeutics (RGLS) correlates with its scientific alliances with pharma behemoths to combat renal pathologies. Diversified oligonucleotide supplies ensure the continuity of research. Future revenues are based on the commercialization of microRNA therapy for rare genetic diseases. The value of 0.00 serves as the current parameter value, capturing the current asset valuation phase on this chart.
Rincian metrik keuangan lan pasar Regulus (RGLS)
- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
- data ekuitas miturut neraca:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas Regulus Therapeutics|RGLS - Koefisien utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Regulus Therapeutics|RGLS - Tanggungan utang kumulatif perusahaan|Utang-utang marang kapitalisasi buku Regulus Therapeutics, Inc.|RGLS - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Regulus Therapeutics|Likuiditas cepet regulusrx.com
- rincian asil keuangan lan kelipatan valuasi:
RGLS - Bathi pungkasan|Proyeksi bathi mangsa ngarep Regulus Therapeutics|RGLS - Pangali P/E|Rega marang bathi mangsa ngarep Regulus Therapeutics Inc|RGLS - Rasio kapitalisasi marang bathi lan wutah|Pangali EV/EBITDA Regulus Therapeutics, Inc.|RGLS - Bathi sadurunge bunga, pajak, lan amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan Regulus Therapeutics|RGLS - Bathi resik saben saham (EPS TTM)|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan regulusrx.com|RGLS - Wutah bathi resik saben siji saham kanggo taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Regulus Therapeutics
Ringkesan analisis perusahaan:Regulus Therapeutics Inc.
Portfolio managers are evaluating the operating model of Regulus Therapeutics (RGLS) through the company's forward P/E ratio, which compares current market capitalization with expected net income to determine the asset's degree of overbought status. The value of 0.00 on the chart reflects market expectations amid a lack of revenue and a dependence on R&D, where any gap between the price and actual successes in RNA therapy signals high volatility.
Pesaing langsung
Prakiraan rega marang bathi TEM (Tempus Labs)|Pangali Forward P/E Qiagen NV (QGEN)|Rega marang bathi mangsa ngarep Ionis Pharma IONS|Repligen Inc. - Rega marang bathi mangsa ngarep|RNA: Prakiraan rega marang bathi|CRSP - Pangali Forward P/E|GeneDx (WGS) - Rega marang bathi mangsa ngarep|RARE - Kapitalisasi marang proyeksi bathi|Prakiraan rega marang bathi BEAM|SRPT: Pangali mangsa ngarep rega marang bathi|Prakiraan rega marang bathi TWST (Twist Bioscience)|Rasio kapitalisasi marang bathi mangsa ngarep TXG|Pangali Forward P/E NTLA (Intellia Therapeutics, Inc.)|Pangali mangsa ngarep rega marang bathi STOK|BioLife Corp - Pangali Forward P/E|Rasio prakiraan rega marang bathi Wave Pharma|Maze Therapeutics Inc (MAZE) - Rega marang bathi mangsa ngarep|sionnatx.com - Pangali mangsa ngarep rega marang bathi|PRME (Prime Medicine) - Pangali Forward P/E|Pangali Forward P/E Taysha Gene Therapies Inc|Rega marang bathi mangsa ngarep uniQure Corp (QURE)|MGTX: Rasio rega marang bathi sing dikarepake|Pangali Forward P/E RGNX (REGENXBIO Inc.)|solidbio.com (SLDB) - Rasio prakiraan rega marang bathi|OCGN: Prakiraan rega marang bathi|PACB - Pangali Forward P/E|BNTC (Benitec) - Prakiraan rega marang bathi|DSGN: Rasio kapitalisasi marang bathi mangsa ngarep|RCKT (Rocket Pharmaceuticals) - Pangali Forward P/E|4dmoleculartherapeutics.com (FDMT) - Kapitalisasi marang proyeksi bathi|Pangali Forward P/E LXEO|Prakiraan rega marang bathi korrobio.com KRRO|Rega marang bathi mangsa ngarep Editas EDIT|Kapitalisasi marang proyeksi bathi Silence Therapeutics Corp (SLN)|PRQR - Rega marang bathi mangsa ngarep|Pangali mangsa ngarep rega marang bathi CDXS (Codexis, Inc.)|SGMO: Pangali Forward P/E|Pangali forward rega marang bathi Nautilus Bio NAUT|Rega marang bathi mangsa ngarep Metagenomi, Inc|Rega marang bathi mangsa ngarep DTIL|Rega marang bathi mangsa ngarep Generation Bio Co. (GBIO)|Kapitalisasi marang proyeksi bathi boundlessbio.com|Pangali Forward P/E XCUR (Exicure)|IMNN: Rasio rega marang bathi mangsa ngarep|PHIO - Rega marang bathi mangsa ngarep|MBIO (Mustang Bio, Inc.) - Rasio rega marang bathi mangsa ngarep|RNAZ: Pangali Forward P/E|Bionano Genomics (BNGO) - Pangali Forward P/E|Rega marang bathi mangsa ngarep Applied DNA Sciences, Inc.|BLUE: Pangali mangsa ngarep rega marang bathi|Pangali Forward P/E IPA|OMGA - Rasio prakiraan rega marang bathi|Pangali Forward P/E OMIC (Singular Genomics Systems)|Pangali forward rega marang bathi syros.com|TBIO: Prakiraan rega marang bathi|TCON - Pangali Forward P/E|Unity Bio (UBX) - Rega marang bathi mangsa ngarep
